Protection against lethal bacterial infection in mice by monocyte-chemotactic and -activating factor.
Chemotactic factors regulate the recruitment of neutrophils, lymphocytes, or monocytes-macrophages to infectious and inflammatory sites. The purpose of this study was to determine whether monocyte-chemotactic and -activating factor (MCAF [MCP-1], a JE gene product) also influences the host defense mechanism against microbial infection. We evaluated the effect of recombinant human MCAF on the survival rate of mice systemically infected with Pseudomonas aeruginosa or Salmonella typhimurium. The administration of 2.5 micrograms of MCAF 6 h before infection completely protected the mice from lethal infection. Mice with cyclophosphamide-induced leukopenia exhibiting increased susceptibility to P. aeruginosa were also endowed with resistance by the same dose of MCAF. Administration of MCAF at -6 h was critical, since MCAF given either earlier or later than -6 h failed to rescue mice from lethal infection. The in vivo effect on the survival of mice paralleled the reduced recovery of viable P. aeruginosa or S. typhimurium from the peritoneal cavity, i.e., the number of recovered bacteria from the MCAF (2.5 micrograms per mouse)-treated mice was reduced to less than 2% of control mice for P. aeruginosa and 4% of control mice for S. typhimurium at 24 h. Since MCAF exhibited chemotaxis on murine macrophages as well as enhanced phagocytosis and killing of bacteria in vitro, the activation of macrophages, followed by the recruitment into the peritoneal cavity, is responsible for eliminating bacteria and thus enhancing the survival rate.
Nakano
Y
Y
Department of Microbiology, Jichi Medical School, Tochigi-ken, Japan.
Kasahara
T
T
Mukaida
N
N
Ko
Y C
YC
Nakano
M
M
Matsushima
K
K
D000818:Animals; D018932:Chemokine CCL2; D002630:Chemotactic Factors / Q000008:administration & dosage / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D002633:Chemotaxis; D016207:Cytokines / Q000008:administration & dosage / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D004195:Disease Models, Animal; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007970:Leukopenia / Q000150:complications / Q000628:therapy; D008262:Macrophage Activation; D017737:Macrophages, Peritoneal / Q000276:immunology; D051379:Mice; D008807:Mice, Inbred BALB C; D008809:Mice, Inbred C3H; D009500:Neutralization Tests; D010529:Peritoneal Cavity / Q000382:microbiology; D010587:Phagocytosis; D011552:Pseudomonas Infections / Q000276:immunology / Q000382:microbiology / Q000517:prevention & control*; D011994:Recombinant Proteins / Q000494:pharmacology; D012481:Salmonella Infections, Animal / Q000276:immunology / Q000382:microbiology / Q000517:prevention & control*; D012486:Salmonella typhimurium / Q000276:immunology / Q000302:isolation & purification
D018932:Chemokine CCL2; D002630:Chemotactic Factors; D016207:Cytokines; D011994:Recombinant Proteins